Long-Term Safety of Eplontersen for Transthyretin Amyloid Heart Disease
Studies long-term safety of eplontersen in adults with transthyretin amyloid heart disease.
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Atlanta, Aurora, Baltimore, Beverly Hills, Boston, Chapel Hill, Charleston, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Detroit, Durham, Fayetteville, Houston, Indianapolis, Kansas City, La Jolla, Lancaster, Madison, Maywood, Minneapolis, Nashville, New York, Philadelphia, Portland, Richmond, Rochester, Salt Lake City, San Francisco, Scottsdale, Seattle, St Louis, Stanford, Washington D.C., and Weston, United StatesSee the 46 sitesAlso in 19 other countries, 86 sites
- Trial code
- Registry title
- An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 1,400 people, planned
- Started
- 30 Nov 2022
- Expected to end
- Aug 2029
- Type of study
- Interventional
- Treatments tested
- Eplontersen
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who finished a related earlier eplontersen study. Everyone gets eplontersen to check long-term safety.
- Age
- 18 years and older
- Sex
- Men and women can join.
- Disease stage
- ATTR-CM (heart muscle disease caused by transthyretin amyloid). No stage is named in the record.
- Earlier treatment
- People must have finished the treatment period and the end-of-treatment visit of the earlier study ION-682884-CS2, or have an ATTR-CM diagnosis and have taken part satisfactorily in study ISIS 420915-CS101.
Main reasons for not taking part
- Stopped the study drug for good during the earlier study ION 682884-CS2 or ISIS 420915-CS101
- A new or worsening health condition that the investigator or sponsor thinks makes joining unsuitable
- Needing medicines that were not allowed in the earlier study
- Not willing to take vitamin A supplements as the study plan says
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Satisfactory completion of Treatment Period and the End of Treatment Visit of the Index Study (ION-682884-CS2) OR diagnosis of ATTR-CM and satisfactory participation on ISIS 420915- CS101 study as judged by the Investigator and Sponsor
- Investigator is willing to treat the participant with open-label eplontersen
- Willingness to adhere to vitamin A supplementation per protocol
Who cannot take part
- Permanently discontinued study drug administration while participating in the Index Study (ION 682884-CS2) or IST (ISIS 420915-CS101 Study)
- Have any new condition or worsening of an existing condition that in the opinion of the Investigator or Sponsor would make the participant unsuitable for enrolment, or which could interfere with the participant participating in or completing the study, including the need for treatment with medications disallowed in the Index Study
Where in United States
Also in 19 other countries, 86 sites
- Emory Heart and Vascular Center - Emory Clifton CampusAtlanta, United StatesEnrolling by invitation
- Piedmont Heart of FayettevilleAtlanta, United StatesEnrolling by invitation
- University of Colorado Hospital - Anschutz Medical CampusAurora, United StatesEnrolling by invitation
- University of Maryland Medical CenterBaltimore, United StatesEnrolling by invitation
- Cedars-Sinai Medical CenterBeverly Hills, United StatesEnrolling by invitation
- Boston University School of MedicineBoston, United StatesEnrolling by invitation
- Brigham and Women's HospitalBoston, United StatesEnrolling by invitation
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
- University of North Carolina at Chapel HillChapel Hill, United StatesEnrolling by invitation
- Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
- Northwestern UniversityChicago, United StatesEnrolling by invitation
- Carl and Edyth Lindner Research Center at The Christ HospitalCincinnati, United StatesEnrolling by invitation
- Cleveland Clinic - Main CampusCleveland, United StatesEnrolling by invitation
- University Hospitals Cleveland Medical Center*Cleveland, United StatesEnrolling by invitation
- The Ohio State University College of MedicineColumbus, United StatesEnrolling by invitation
- University of Texas Southwestern Medical CenterDallas, United StatesEnrolling by invitation
- Henry Ford Health SystemDetroit, United StatesEnrolling by invitation
- Duke University Medical CenterDurham, United StatesEnrolling by invitation
- Piedmont Atlanta HospitalFayetteville, United StatesEnrolling by invitation
- Houston Methodist HospitalHouston, United StatesEnrolling by invitation
- Indiana University Health University HospitalIndianapolis, United StatesEnrolling by invitation
- Saint Luke's Hospital of Kansas CityKansas City, United StatesEnrolling by invitation
- University of Kansas Medical CenterKansas City, United StatesEnrolling by invitation
- University of Kansas Medical Center (KUMC)Kansas City, United StatesEnrolling by invitation
- Altman Clinical and Translational Research Institute - Center for Clinical ResearchLa Jolla, United StatesEnrolling by invitation
- Lancaster General HospitalLancaster, United StatesEnrolling by invitation
- University of Wisconsin - MadisonMadison, United StatesEnrolling by invitation
- Loyola University Medical CenterMaywood, United StatesEnrolling by invitation
- Allina Health Minneapolis Heart Institute - Abbott Northwestern's Heart HospitalMinneapolis, United StatesEnrolling by invitation
- Vanderbilt Heart and Vascular InstituteNashville, United StatesEnrolling by invitation
- Columbia University Irving Medical CenterNew York, United StatesEnrolling by invitation
- New York University Langone Cardiology AssociatesNew York, United StatesEnrolling by invitation
- Weill Cornell Medicine CardiologyNew York, United StatesEnrolling by invitation
- Penn Presbyterian Medical CenterPhiladelphia, United StatesEnrolling by invitation
- Oregon Health and Science UniversityPortland, United StatesEnrolling by invitation
- Virginia Commonwealth UniversityRichmond, United StatesEnrolling by invitation
- Mayo ClinicRochester, United StatesEnrolling by invitation
- University of UtahSalt Lake City, United StatesEnrolling by invitation
- University Of California San Francisco Urology PracticeSan Francisco, United StatesEnrolling by invitation
- Mayo ClinicScottsdale, United StatesEnrolling by invitation
- University of WashingtonSeattle, United StatesEnrolling by invitation
- Barnes-Jewish HospitalSt Louis, United StatesEnrolling by invitation
- Stanford University (Leland Stanford Junior University)Stanford, United StatesEnrolling by invitation
- MedStar Washington Hospital CenterWashington D.C., United StatesEnrolling by invitation
- The George Washington Medical Faculty Associates - Foggy Bottom North PavilionWashington D.C., United StatesEnrolling by invitation
- Cleveland Clinic FloridaWeston, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
The group in the trial
- EplontersenTreatment being tested
Eplontersen will be administered once every month by sub-cutaneous (SC) injection for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Plain-language title
- Long-Term Safety of Eplontersen for Transthyretin Amyloid Heart DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 April 2026